Abstract
Pilot phase II and toxicity trial of ifosfamide (IFF)/Mesna (M), protracted oral etoposide (VP) and cisplatinum (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) : S.K. Williamson, S.A. Taylor, R.L. Stephens, R. Sadasivan, R. McKittrick, P. Van Veldhuizen and J. Turner, Kansas City Veterans Affairs Medical Center, Kansas City, MO. and University of Kansas Medical Center, Kansas City, KS
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
